NO20013938L - Essensielle fettsyrer ved forebyggelse av kardiovaskul¶re hendelser - Google Patents

Essensielle fettsyrer ved forebyggelse av kardiovaskul¶re hendelser

Info

Publication number
NO20013938L
NO20013938L NO20013938A NO20013938A NO20013938L NO 20013938 L NO20013938 L NO 20013938L NO 20013938 A NO20013938 A NO 20013938A NO 20013938 A NO20013938 A NO 20013938A NO 20013938 L NO20013938 L NO 20013938L
Authority
NO
Norway
Prior art keywords
fatty acids
essential fatty
dha
epa
patient
Prior art date
Application number
NO20013938A
Other languages
English (en)
Other versions
NO328797B1 (no
NO20013938D0 (no
Inventor
Franco Pamparana
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11381919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20013938(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of NO20013938L publication Critical patent/NO20013938L/no
Publication of NO20013938D0 publication Critical patent/NO20013938D0/no
Publication of NO328797B1 publication Critical patent/NO328797B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20013938A 1999-02-17 2001-08-14 Anvendelse av essensielle fettsyrer inneholdende en blanding av eikosapentaensyreetylester (EPA) og docosaheksaensyreetylester (DHA) for fremstilling av et medikament nyttig ved forebyggelse av dodsfall hos en pasient som har hatt et hjerteinfarkt. NO328797B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI000313A IT1308613B1 (it) 1999-02-17 1999-02-17 Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
PCT/EP2000/000957 WO2000048592A1 (en) 1999-02-17 2000-02-07 Essential fatty acids in the prevention of cardiovascular events

Publications (3)

Publication Number Publication Date
NO20013938L true NO20013938L (no) 2001-08-14
NO20013938D0 NO20013938D0 (no) 2001-08-14
NO328797B1 NO328797B1 (no) 2010-05-18

Family

ID=11381919

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013938A NO328797B1 (no) 1999-02-17 2001-08-14 Anvendelse av essensielle fettsyrer inneholdende en blanding av eikosapentaensyreetylester (EPA) og docosaheksaensyreetylester (DHA) for fremstilling av et medikament nyttig ved forebyggelse av dodsfall hos en pasient som har hatt et hjerteinfarkt.

Country Status (26)

Country Link
US (2) US7462643B1 (no)
EP (2) EP1152755B1 (no)
JP (2) JP5441287B2 (no)
KR (2) KR100823051B1 (no)
CN (1) CN1230159C (no)
AT (1) ATE216230T1 (no)
AU (1) AU775078B2 (no)
BR (1) BR0008153A (no)
CA (1) CA2362271C (no)
CZ (1) CZ301307B6 (no)
DE (1) DE60000133C5 (no)
DK (1) DK1152755T3 (no)
EA (1) EA004312B1 (no)
ES (1) ES2174814T3 (no)
HK (1) HK1044720B (no)
HU (1) HUP0200111A3 (no)
ID (1) ID30205A (no)
IL (2) IL144377A0 (no)
IT (1) IT1308613B1 (no)
NO (1) NO328797B1 (no)
NZ (1) NZ513093A (no)
PL (1) PL209078B1 (no)
PT (1) PT1152755E (no)
SK (1) SK286523B6 (no)
WO (1) WO2000048592A1 (no)
ZA (1) ZA200106029B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it) * 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
BR0309740A (pt) 2002-05-03 2005-02-22 Pronova Biocare As Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmos
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
MX291518B (es) * 2004-04-16 2011-10-31 Solvay Pharm Gmbh Acidos grasos esenciales en la prevencion y/o el tratamiento de depresion en pacientes con enfermedad cardiaca coronarias o arterial coronaria.
CA2601985C (en) 2005-03-11 2013-07-16 Recon Oil Industries Private Limited A synergistically heat stable oil media having eicosa pentaenoic acid (epa) and do-cosa hexaenoic acid (dha)
KR101465715B1 (ko) * 2005-07-08 2014-11-27 모치다 세이야쿠 가부시키가이샤 심혈관 이벤트 발병 예방용 조성물
JP5134916B2 (ja) * 2005-07-08 2013-01-30 持田製薬株式会社 心血管イベント発症予防用組成物
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
EP3263101A1 (en) 2005-12-21 2018-01-03 Brudy Technology, S.L. Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
EP2526937A1 (en) 2006-02-07 2012-11-28 Mochida Pharmaceutical Co., Ltd. Composition for prevention of recurrence of stroke
EP2777701A1 (en) * 2006-05-31 2014-09-17 Mochida Pharmaceutical Co., Ltd. Composition for preventing the occurrence of a cardiovascular event in multiple risk patient comprising the ethyl ester of all-cis-5,8,11,14,17-icosapentaenoic acid
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
EP2323647B1 (en) * 2008-08-07 2014-09-10 SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A. Long-term treatment of symptomatic heart failure
JPWO2010018856A1 (ja) * 2008-08-13 2012-01-26 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
EP2475309A4 (en) * 2009-09-08 2015-07-29 Atrium Medical Corp HERNIAPFLASTER
CA2873141C (en) 2009-12-30 2018-05-29 Adam Kelliher Simulated moving bed chromatographic separation process
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
KR101681907B1 (ko) * 2012-02-27 2016-12-12 주식회사 케어사이드 혈액 순환 촉진 및 피부 질환 개선용 조성물
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
EP2830602B1 (en) 2012-03-30 2020-10-21 Micelle BioPharma, Inc. Omega-3 fatty acid ester compositions
WO2014057362A2 (en) * 2012-09-24 2014-04-17 Aker Biopharma As Omega -3 compositions
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
EP2883860B1 (fr) 2013-12-11 2016-08-24 Novasep Process Procédé chromatographique de production d'acides gras polyinsaturés
JP6303017B2 (ja) 2014-01-07 2018-03-28 ノヴァセプ プロセスＮｏｖａｓｅｐ Ｐｒｏｃｅｓｓ 芳香族アミノ酸を精製する方法
PL237374B1 (pl) * 2017-11-10 2021-04-06 Lambdafin Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna zawierająca mieszaninę estru etylowego kwasu eikozapentaenowego i estru etylowego kwasu dokozaheksaenowego oraz jej zastosowanie

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034156A (ja) * 1983-08-08 1985-02-21 Hayashibara Biochem Lab Inc エイコサペンタエン酸包接化合物及びこれを含有した飲食物
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
NO157302C (no) 1985-12-19 1988-02-24 Norsk Hydro As Fremgangsmaate for fremstilling av et fiskeoljekonsentrat.
US4920098A (en) 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
IT1205043B (it) 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
GB2218984B (en) 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5059622A (en) * 1989-08-29 1991-10-22 Biosyn, Inc. Method for reducing blood pressure levels in hypertensive persons
JP2893866B2 (ja) 1990-05-25 1999-05-24 日本油脂株式会社 抗不整脈薬
US5324323A (en) 1992-09-09 1994-06-28 Telectronics Pacing Systems, Inc. Multiple channel cardiosynchronous myoplasty apparatus
US5208236A (en) 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use
WO1994013642A1 (de) 1992-12-11 1994-06-23 Ciba-Geigy Ag Substituierte benzazepinone
CN1082909A (zh) * 1993-01-03 1994-03-02 潘玉珍 精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂
JPH07118229A (ja) 1993-10-19 1995-05-09 Fujisawa Pharmaceut Co Ltd 尿素誘導体およびその製造法
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
JPH0812581A (ja) 1994-06-30 1996-01-16 Fujirebio Inc 虚血性心疾患治療剤
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
WO1998010085A2 (en) 1996-09-05 1998-03-12 The Regents Of The University Of California Gene therapy for congestive heart failure
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
US6333447B1 (en) 1996-03-29 2001-12-25 The General Hospital Corporation Transgenic model of heart failure
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6313167B1 (en) 1997-06-16 2001-11-06 Nippon Suisan Kaisha Ltd. Composition having capability of removing risk factor during exercise
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
EP1130027A1 (de) 2000-02-29 2001-09-05 Aventis Pharma Deutschland GmbH Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben

Also Published As

Publication number Publication date
PL350851A1 (en) 2003-02-10
EA200100895A1 (ru) 2002-02-28
CN1230159C (zh) 2005-12-07
ITMI990313A1 (it) 2000-08-17
EP1152755B1 (en) 2002-04-17
ZA200106029B (en) 2002-09-25
HUP0200111A2 (hu) 2002-05-29
AU2907500A (en) 2000-09-04
KR20070098954A (ko) 2007-10-05
NZ513093A (en) 2003-02-28
EP1152755A1 (en) 2001-11-14
JP5441287B2 (ja) 2014-03-12
DE60000133C5 (de) 2014-02-27
AU775078B2 (en) 2004-07-15
US20090018193A1 (en) 2009-01-15
WO2000048592A1 (en) 2000-08-24
DE60000133D1 (de) 2002-05-23
KR20010102183A (ko) 2001-11-15
ID30205A (id) 2001-11-15
DK1152755T3 (da) 2002-07-22
HK1044720B (zh) 2006-08-18
JP2010116414A (ja) 2010-05-27
EA004312B1 (ru) 2004-02-26
SK286523B6 (sk) 2008-12-05
DE60000133T2 (de) 2002-11-21
IL144377A (en) 2006-12-10
CA2362271A1 (en) 2000-08-24
PL209078B1 (pl) 2011-07-29
HK1044720A1 (en) 2002-11-01
ATE216230T1 (de) 2002-05-15
NO328797B1 (no) 2010-05-18
JP2002537252A (ja) 2002-11-05
CA2362271C (en) 2008-07-15
BR0008153A (pt) 2001-11-06
IT1308613B1 (it) 2002-01-09
EP1247523A1 (en) 2002-10-09
CZ301307B6 (cs) 2010-01-06
NO20013938D0 (no) 2001-08-14
CZ20012947A3 (cs) 2002-04-17
KR100823051B1 (ko) 2008-04-18
HUP0200111A3 (en) 2003-03-28
PT1152755E (pt) 2002-09-30
IL144377A0 (en) 2002-05-23
ES2174814T3 (es) 2002-11-16
CN1343120A (zh) 2002-04-03
SK10802001A3 (sk) 2001-12-03
US7462643B1 (en) 2008-12-09

Similar Documents

Publication Publication Date Title
NO20013938D0 (no) Essensielle fettsyrer ved forebyggelse av kardiovaskulore hendelser
US5198468A (en) Essential fatty acid composition
US4666701A (en) Pharmaceutical and dietary compositions
YU59303A (sh) Esencijalne n-3 masne kiseline u lečenju srčane insuficijencije i manjkavosti rada srca
GB9907715D0 (en) Pharmaceutical compositions
PT1310249E (pt) Utilizacao de acidos gordos poli-insaturados para prevencao primaria de eventos cardiovasculares graves
KR940018090A (ko) 트리글리세라이드
FI970298A0 (fi) DHA:n käyttö farmaseuttisena koostumuksena
CA2166204A1 (en) Pharmaceutical compositions for sparingly soluble therapeutic agents
DK0623019T3 (da) Medikamenter på basis af docosahexaensyre som midler mod blodpladeaggregation og mod cerebral mangel på essentielle fedtsyr
NZ217703A (en) 2-(2-fluoro-4-biphenylyl) propionic acid compositions
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
CA2302641A1 (en) Liver fat accumulation inhibitory composition, food additive for liver fat accumulation inhibition, and method of inhibiting liver fat accumulation
CN1212867A (zh) 防治心脑血管疾病的组合物
MY130474A (en) Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants
WO1993009773A1 (fr) Composition servant a prevenir ou a traiter la dysmenorrhee et aliment ayant une fonction de prevention de la dysmenorrhee
TH15808A (th) ไทรกลีเซอไรด์ กรรมวิธีสำหรับการผลิต c-ซับสทิทิว?เทด?ไดเอธิลีนไทรแอมีน
KR940008688A (ko) 필수지방산에 의해 킬레이트화된 아연정제
RU99109049A (ru) Фармацевтический препарат, содержащий эйкозапентаеновую кислоту и/или стеаридоновую кислоту

Legal Events

Date Code Title Description
MK1K Patent expired